BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies

Stock Information for Immuron Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Immuron Limited

BriaCell Announces Oral and Poster Presentations at ASCO 2024
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+(TM) and Bria-PROS+(TM) Clinical Candidates for Breast and Prostate Cancer
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference
BriaCell Provides Update on Alleged Illegal Trading of Public Securities
BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.